TY - T1的一个长期研究的有效性Levodopa-carbidopa肠凝胶治疗先进的帕金森症患者(P5.066) JF -神经学乔-神经学六世- 90 - 15补充SP - P5.066盟k . Ray乔杜里AU -安吉洛Antonini盟Werner Poewe盟每奥丁-大卫Standaert盟盟首页-豪尔赫Zamudio盟Lars伯格曼Y1 - 2018/04/10 UR - //www.ez-admanager.com/content/90/15_Supplement/P5.066.abstract N2 -目的:展示设计和基线特征从一个正在进行的全球研究评估长期的有效性Levodopa-carbidopa肠凝胶(LCIG)治疗晚期帕金森病(PD)患者在常规临床护理。背景:LCIG通过经皮胃空肠吻合术,提高“关闭”时间,运动障碍,非症状(NMS),和先进的PD患者的生活质量(QoL)。然而,潜在的长期数据的有效性LCIG在常规临床实践是有限的。设计/方法:这个全球多中心,随访时间,开放的观察性研究先进的PD患者LCIG跨越3年常规临床护理(DUOGLOBE),并且是第一个LCIG在美国进行的观察研究。大约200例50岁以上的全球中心正在登记根据当地产品标签。主要功效的结果是“关闭”意味着改变时间。(二次端点包括运动障碍持续时间和严重程度评估UPDRS IV和统一运动障碍评定量表)、日常生活活动(UPDRS-II)、运动机能(UPDRS-III)和波动(UPDRS 39项),生命质量(8 PD问卷),和NMS,包括睡眠/白天嗜睡与NMS量表评估,PD睡眠量表(PDSS-2)和埃普沃思嗜睡量表。如何衡量和不良事件监测照顾者负担。结果:截止2016年12月16日,基线人口统计学和疾病特征对29个病人。均值(SD)基线年龄,PD持续时间、睡眠时间、运动障碍持续时间,和“关闭”时间是69.7(8.3),11.7(5.1),8.2(1.8)小时,3.8小时(3.6),和6.4(3.4)小时,分别。27例(93.1%)病人是白色和11(37.9%)是女性。Conclusions: Long-term effectiveness data on LCIG in the treatment of advanced PD patients under routine clinical care is limited, especially long-term, prospective data related to dyskinesia, NMS, QoL, and caregiver burden. The current study is designed to provide a better understanding of the long-term effectiveness profile of LCIG for the treatment of advanced PD.Study Supported by: AbbVie Inc.Disclosure: Dr. Chaudhuri has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc., Voyager Therapeutics, and Serina Therapeutics. Dr. Chaudhuri has received research support from AbbVie Inc. Dr. Antonini has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, Boston Scientific, Boheringer Ingelheim, AbbVie Inc., Zambon. Dr. Antonini has received research support from Mundipharma. Dr. Poewe has nothing to disclose. Dr. Standaert has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Voyager Therapeutics, and Serina Therapeutics. Dr. Standaert has received research support from AbbVie. Dr. Odin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc., Britannia, Boehringer-Ingelheim, Nordic Infucare, UCB and Zambon PO har received royalities from Uni-Med Verlag. Dr. Zamudio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Zamudio holds stock and/or stock options in AbbVie Inc. Dr. Bergmann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Bergmann holds stock and/or stock options in AbbVie Inc. ER -